Moolec Science Net Income From Continuing Ops Over Time
| MLEC Stock | 5.37 1.13 17.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Moolec Science Performance and Moolec Science Correlation. Will Biotechnology sector continue expanding? Could Moolec diversify its offerings? Factors like these will boost the valuation of Moolec Science. Expected growth trajectory for Moolec significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Moolec Science data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (258.69) | Revenue Per Share | Quarterly Revenue Growth 9.483 | Return On Assets | Return On Equity |
Investors evaluate Moolec Science SA using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Moolec Science's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Moolec Science's market price to deviate significantly from intrinsic value.
Understanding that Moolec Science's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moolec Science represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Moolec Science's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Moolec Science SA and related stocks such as Virax Biolabs Group, Elevai Labs Common, and NKGen Biotech Common Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRAX | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (672.9 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| ELAB | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (1.8 M) | (4.3 M) | (4 M) | (3.6 M) | (3.8 M) |
| GLMD | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (20.5 M) | (28.8 M) | (32.5 M) | (17.9 M) | (7.5 M) | (7.5 M) | (6.8 M) | (7.1 M) |
| WINT | (24.5 M) | (24.5 M) | (37.9 M) | (46 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (32.6 M) | (67.6 M) | (39.2 M) | (20.3 M) | (1.8 M) | (2.1 M) | (2.2 M) |
| GTBP | (23.5 M) | (23.5 M) | (23.5 M) | (23.5 M) | (23.5 M) | (21.5 M) | 21 M | (143.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (10.2 M) | (13.2 M) | (15.1 M) | (15.9 M) |
| TIVC | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (3.6 M) | (8.5 M) | (10.1 M) | (8.2 M) | (5.7 M) | (5.1 M) | (5.3 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.3 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| XRTX | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (3.8 M) | (629.6 K) | (1.3 M) | (1.7 M) | (7 M) | (2.2 M) | (3.3 M) | (3 M) | (3.1 M) |
| NCEL | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (22.7 M) | (12 M) | (26.6 M) | (30.5 M) | (32.1 M) |
Moolec Science SA and related stocks such as Virax Biolabs Group, Elevai Labs Common, and NKGen Biotech Common Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Moolec Science SA | MLEC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 89 Nexus Way, |
| Exchange | NASDAQ Exchange |
null 5.37
Check out Moolec Science Performance and Moolec Science Correlation. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Moolec Science technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.